[Federal Register Volume 87, Number 99 (Monday, May 23, 2022)]
[Notices]
[Pages 31237-31238]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-10991]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-22-0009; Docket No. CDC-2022-0069]


Proposed Data Collection Submitted for Public Comment and 
Recommendations

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice with comment period.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), as part 
of its continuing effort to reduce public burden and maximize the 
utility of government information, invites the general public and other 
federal agencies the opportunity to comment on a continuing information 
collection, as required by the Paperwork Reduction Act of 1995. This 
notice invites comment on a proposed information collection project 
titled National Disease Surveillance Program. This collection covers 
the surveillance activities for four rare disease conditions; 
Creutzfeldt-Jakob Disease (CJD), Reye Syndrome, Kawasaki Syndrome, and 
Acute Flaccid Myelitis (AFM).

DATES: CDC must receive written comments on or before July 22, 2022.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2022-
0069 by either of the following methods:
     Federal eRulemaking Portal: www.regulations.gov. Follow 
the instructions for submitting comments.
     Mail: Jeffrey M. Zirger, Information Collection Review 
Office, Centers for Disease Control and Prevention, 1600 Clifton Road 
NE, MS H21-8, Atlanta, Georgia 30329.
    Instructions: All submissions received must include the agency name 
and Docket Number. CDC will post, without

[[Page 31238]]

change, all relevant comments to www.regulations.gov.
    Please note: Submit all comments through the Federal eRulemaking 
portal (regulations.gov) or by U.S. mail to the address listed above.

FOR FURTHER INFORMATION CONTACT: To request more information on the 
proposed project or to obtain a copy of the information collection plan 
and instruments, contact Jeffrey M. Zirger, Information Collection 
Review Office, Centers for Disease Control and Prevention, 1600 Clifton 
Road NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7570; 
Email: [email protected].

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 
(PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from 
the Office of Management and Budget (OMB) for each collection of 
information they conduct or sponsor. In addition, the PRA also requires 
federal agencies to provide a 60-day notice in the Federal Register 
concerning each proposed collection of information, including each new 
proposed collection, each proposed extension of existing collection of 
information, and each reinstatement of previously approved information 
collection before submitting the collection to the OMB for approval. To 
comply with this requirement, we are publishing this notice of a 
proposed data collection as described below.
    The OMB is particularly interested in comments that will help:
    1. Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    2. Evaluate the accuracy of the agency's estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    3. Enhance the quality, utility, and clarity of the information to 
be collected; and
    4. Minimize the burden of the collection of information on those 
who are to respond, including through the use of appropriate automated, 
electronic, mechanical, or other technological collection techniques or 
other forms of information technology, e.g., permitting electronic 
submissions of responses; and
    5. Assess information collection costs.

Proposed Project

    National Disease Surveillance Program (OMB Control No. 0920-0009, 
Exp. 8/31/2022)--Revision--National Center for Emerging and Zoonotic 
Infectious Diseases (NCEZID), Centers for Disease Control and 
Prevention (CDC).

Background and Brief Description

    Surveillance of the incidence and distribution of disease has been 
an important function of the U.S. Public Health Service (PHS) since an 
1878 Act of Congress authorized the PHS to collect morbidity reports. 
After the Malaria Control in War Areas Program had fulfilled its 
original 1942 objective of reducing malaria transmission, its basic 
tenets were carried forward and broadened by the formation of the 
Communicable Disease Center (CDC) in 1946. CDC was conceived of as a 
well-equipped, broadly staffed agency used to translate facts about 
analysis of morbidity and mortality statistics on communicable diseases 
and through field investigations. It was soon recognized that control 
measures (such as the DDT spraying for malaria) did not alleviate the 
threat of disease reintroduction. In 1950, the Malaria Surveillance 
Program began and in 1952, the National Surveillance Program started. 
Both programs were based on the premise that diseases cannot be 
diagnosed, prevented, or controlled until existing knowledge is 
expanded and new ideas developed and implemented. The original scope of 
the National Surveillance Program included the study of malaria, murine 
typhus, smallpox, psittacosis, diphtheria, leprosy, and sylvatic 
plague. Over the years, the mandate of CDC has broadened in preventive 
health activities and the surveillance systems maintained have 
expanded.
    The National Disease Surveillance Program is authorized under the 
Public Health Service Act, Section 301 and 306 (42 U.S.C. 241 and 
242K). This information collection activity covers surveillance 
activities for four, rare diseases: (1) Creutzfeldt-Jakob Disease 
(CJD), (2) Reye Syndrome, (3) Kawasaki Syndrome, and (4) Acute Flaccid 
Myelitis. Since the previous approval of 0920-0009, changes are being 
requested only to the Acute Flaccid Myelitis form. The total estimated 
burden requested by CDC has been reduced to 98, down 69 hours from the 
previous total of 167, and is adjusted to match actual, experienced 
burden more closely. There is no cost to respondents other than the 
time to participate.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                     Number of    Average burden
      Type of respondents           Form name        Number of     responses per   per response    Total burden
                                                    respondents     respondent      (in hours)      (in hours)
----------------------------------------------------------------------------------------------------------------
Epidemiologist................  CJD.............              10               2           20/60               7
                                Kawasaki                      20               2           15/60              10
                                 Syndrome.
                                Reye Syndrome1..               1               1           20/60               1
                                Acute Flaccid                100               4           12/60              80
                                 Myelitis.
                                                 ---------------------------------------------------------------
    Total.....................  ................  ..............  ..............  ..............              98
----------------------------------------------------------------------------------------------------------------


Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific 
Integrity, Office of Science, Centers for Disease Control and 
Prevention.
[FR Doc. 2022-10991 Filed 5-20-22; 8:45 am]
BILLING CODE 4163-18-P